Carotid Artery Wall Ultrasound as a Heart Risk Marker in Type 2 Diabetes
Compares carotid artery ultrasound images in people with and without type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus
Key facts
- Where
- Elche, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 69 years old?
Source: NCT07373938, who can take part
Where in Spain
- Francisco Javier Molina PayáElche, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cardenal Herrera University
- Trial code
- NCT07373938
- Record updated
- 20 October 2026
- Original description
This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.Read full original descriptionShow less
Carotid Wall Layer Texture as a Potential Biomarker for Cardiovascular Risk Assessment in Preventive Nursing: a Study in Type 2 Diabetes Mellitus
This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.
Inclusion: European adults; Age between 40 and 69 years; Confirmed diagnosis of type 2 diabetes mellitus; No established cardiovascular disease; Availability of the required clinical and metabolic variables: Age; Sex; Systolic blood pressure; Non-high-density lipoprotein (non-HDL) cholesterol; Smoking status; Duration of diabetes; Glycated hemoglobin (HbA1c); Presence or absence of diabetes-related target organ damage (e.g., albuminuria, retinopathy).
Exclusion: History of clinical cardiovascular disease (secondary prevention); Type 1 diabetes mellitus; Patients with established severe target organ damage or conditions that automatically classify them as very high cardiovascular risk according to ESC guidelines; Advanced chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m²).